Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Cesano Alessandra | Director | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 62,150 | $9.12 | $566,808 | 56,700Direct | Form 4 filed 16 Sep 2026, on sec.gov (opens in a new tab)Filed 16 Sep 2026 | |
| Cesano Alessandra | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherM · Option or derivative exercised or converted | 50,000 | $2.93 | $146,500 | 118,850Direct | Form 4 filed 16 Sep 2026, on sec.gov (opens in a new tab)Filed 16 Sep 2026 | |
| WILSON TROY EDWARD | Director | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 5,000 | $9.10 | $45,500 | 54,750Direct | Form 4 filed 16 Sep 2026, on sec.gov (opens in a new tab)Filed 16 Sep 2026 | |
| AUERBACH ALAN H | Director, President and CEO, 10% owner | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 44,058 | $8.26 | $363,919.08 | 7,261,671Direct | Form 4 filed 8 Jul 2026, on sec.gov (opens in a new tab)Filed 8 Jul 2026 | |
| HUNT DOUGLAS M | See Remarks | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 8,460 | $8.26 | $69,879.60 | 196,841Direct | Form 4 filed 8 Jul 2026, on sec.gov (opens in a new tab)Filed 8 Jul 2026 | |
| NOUGUES MAXIMO F | Chief Financial Officer | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 9,386 | $8.26 | $77,528.36 | 230,637Direct | Form 4 filed 8 Jul 2026, on sec.gov (opens in a new tab)Filed 8 Jul 2026 | |
| Dorval Allison | Director | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 11,610 | $7.20 | $83,592 | 90,780Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| Senderowicz Adrian | Director | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 27,000 | $7.20 | $194,400 | 27,000Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| MOYES JAY M | Director | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 22,000 | $7.22 | $158,840 | 58,322Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| Stuglik Brian M | Director | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 8,100 | $7.20 | $58,320 | 113,858Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| WILSON TROY EDWARD | Director | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 10,800 | $7.20 | $77,760 | 59,750Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| Dorval Allison | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 27,000 | $0.00 | $0 | 102,390Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| Senderowicz Adrian | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 27,000 | $0.00 | $0 | 54,000Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| MOYES JAY M | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 27,000 | $0.00 | $0 | 80,322Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| Stuglik Brian M | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 27,000 | $0.00 | $0 | 121,958Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| WILSON TROY EDWARD | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 27,000 | $0.00 | $0 | 70,550Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| MILLER MICHAEL PATRICK | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 27,000 | $0.00 | $0 | 81,000Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| Cesano Alessandra | Director | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 27,000 | $0.00 | $0 | 68,850Direct | Form 4 filed 15 Jun 2026, on sec.gov (opens in a new tab)Filed 15 Jun 2026 | |
| NOUGUES MAXIMO F | Chief Financial Officer | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 46,739 | $0.00 | $0 | 240,023Direct | Form 4 filed 20 Feb 2026, on sec.gov (opens in a new tab)Filed 20 Feb 2026 | |
| AUERBACH ALAN H | Director, President and CEO, 10% owner | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 159,778 | $0.00 | $0 | 7,305,729Direct | Form 4 filed 20 Feb 2026, on sec.gov (opens in a new tab)Filed 20 Feb 2026 | |
| HUNT DOUGLAS M | See Remarks | PUMA BIOTECHNOLOGY, INC.PBYI | OtherA · Grant or award from the company | 49,394 | $0.00 | $0 | 205,301Direct | Form 4 filed 20 Feb 2026, on sec.gov (opens in a new tab)Filed 20 Feb 2026 | |
| HUNT DOUGLAS M | See Remarks | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 5,014 | $5.88 | $29,482.32 | 155,907Direct | Form 4 filed 8 Jan 2026, on sec.gov (opens in a new tab)Filed 8 Jan 2026 | |
| AUERBACH ALAN H | Director, President and CEO, 10% owner | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 18,012 | $5.88 | $105,910.56 | 7,145,951Direct | Form 4 filed 8 Jan 2026, on sec.gov (opens in a new tab)Filed 8 Jan 2026 | |
| NOUGUES MAXIMO F | Chief Financial Officer | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 6,405 | $5.88 | $37,661.40 | 193,284Direct | Form 4 filed 8 Jan 2026, on sec.gov (opens in a new tab)Filed 8 Jan 2026 | |
| HUNT DOUGLAS M | See Remarks | PUMA BIOTECHNOLOGY, INC.PBYI | SellS · Open-market or private sale | 3,973 | $5.84 | $23,202.32 | 160,921Direct | Form 4 filed 8 Jan 2026, on sec.gov (opens in a new tab)Filed 8 Jan 2026 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.